These Are The Five Best And Worst Performing Penny Stocks Of 2022 (So Far)24/7 Wall Street • 09/03/22
Trevi Therapeutics Announces Multiple Late-Breaking Abstracts Accepted for Presentation at Upcoming Medical Conferences on Analysis of Oral Nalbuphine Extended ReleasePRNewsWire • 08/24/22
Trevi Therapeutics, Inc. Discusses Commercialization for Its Investigational Therapy, Haduvio, with The Stock Day PodcastNewsfile Corp • 08/22/22
Trevi Therapeutics, Inc. (TRVI) CEO Jennifer Good on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/14/22
Trevi Therapeutics Announces Second Quarter 2022 Financial Results and Business UpdatePRNewsWire • 08/11/22
Trevi Therapeutics to Report Q2 2022 Financial Results and Provide a Corporate Update on August 11, 2022PRNewsWire • 08/04/22
Traders News Source Senior Editor Mark Roberts Interviews Jennifer Good CEO of Trevi TherapeuticsAccesswire • 07/14/22
Trevi Therapeutics to Attend the Twelfth London International Cough Symposium (12th LICS)PRNewsWire • 07/07/22
Trevi Therapeutics Reports Positive Results from the Ph2b/3 PRISM Trial of Haduvio™ in the Treatment of Prurigo NodularisPRNewsWire • 06/29/22
Trevi Therapeutics to Present and Participate in Partnership Meetings at Upcoming 2022 BIO International ConventionPRNewsWire • 06/07/22
Trevi Therapeutics' (TRVI) CEO Jennifer Good on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/14/22
Trevi Therapeutics Announces First Quarter 2022 Financial Results and Business UpdatePRNewsWire • 05/12/22
Trevi Therapeutics to Report Q1 2022 Financial Results and Provide a Corporate Update on May 12, 2022PRNewsWire • 05/05/22
Are You Looking for a Top Momentum Pick? Why Trevi Therapeutics, Inc. (TRVI) is a Great ChoiceZacks Investment Research • 04/13/22